Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease: A Prospective Study Based on Clinical Risk Stratification
Files
Publication date
2023-02-01
Authors
Arkenbosch, Jeanine H.C.
Beelen, Evelien M.J.
Dijkstra, Gerard
Romberg-Camps, Mariëlle
Duijvestein, Marjolijn
Hoentjen, Frank
Van Der Marel, Sander
Maljaars, P. W.Jeroen
Jansen, Sita
De Boer, Nanne K.H.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc
Abstract
Background: To prevent recurrence after ileocolonic resection [ICR] in Crohn's disease [CD], postoperative prophylaxis based on risk stratification is recommended in international guidelines. This study aimed to evaluate postoperative CD recurrence after implementation of a clinical management algorithm and to determine the predictive value of clinical and histological risk factors [RFs]. Methods: In this multicentre, prospective cohort study, CD patients [≥16 years] scheduled for ICR were included. The algorithm advised no postoperative medication for low-risk patients, and treatment with prophylaxis [immunosuppressant/biological] for high-risk patients [≥1 RF: active smoking, penetrating disease, prior ICR]. Clinical and histological RFs [active inflammation, granulomas, plexitis in resection margins] for endoscopic recurrence [Rutgeerts' score ≥i2b at 6 months] were assessed using logistic regression and ROC curves based on predicted probabilities. Results: In total, 213 CD patients after ICR were included [age 34.5 years; 65% women] (93 [44%] low-risk; 120 [56%] high-risk: 45 [38%] smoking; 51 [43%] penetrating disease; 51 [43%] prior ICR). Adherence to the algorithm was 82% in low-risk [no prophylaxis] and 51% in high-risk patients [prophylaxis]. Endoscopic recurrence was higher in patients treated without prophylaxis than with prophylaxis in both low [45% vs 16%, p = 0.012] and high-risk patients [49% vs 26%, p = 0.019]. Clinical risk stratification including the prescription of prophylaxis corresponded to an area under the curve [AUC] of 0.70 (95% confidence interval [CI] 0.61-0.79). Clinical RFs combined with histological RFs increased the AUC to 0.73 [95% CI 0.64-0.81]. Conclusion: Adherence to this management algorithm is 65%. Prophylactic medication after ICR prevents endoscopic recurrence in low- and high-risk patients. Clinical risk stratification has an acceptable predictive value, but further refinement is needed.
Keywords
Crohn's disease, Ileocecal resection, postoperative recurrence, General Medicine
Citation
Arkenbosch, J H C, Beelen, E M J, Dijkstra, G, Romberg-Camps, M, Duijvestein, M, Hoentjen, F, Van Der Marel, S, Maljaars, P W J, Jansen, S, De Boer, N K H, West, R L, Horjus, C S, Stassen, L P S, Van Schaik, F D M, Van Ruler, O, Jharap, B J H, Visschedijk, M, Janssen, A, Erler, N S, Doukas, M, Ooms, A H A G, Kats-Ugurlu, G, Van Der Woude, C J & De Vries, A C 2023, 'Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease : A Prospective Study Based on Clinical Risk Stratification', Journal of Crohn's and Colitis, vol. 17, no. 2, pp. 221-230. https://doi.org/10.1093/ecco-jcc/jjac128